Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Pruritus Therapeutics Market Heading Into 2029?

The market size for pruritus therapeutics has seen a consistent rise in recent years. The market is projected to expand from $11.89 billion in 2024 to $12.38 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors such as an increase in pruritus cases, a range of causative factors and conditions, a growing elderly population, and a focus on improving the patient’s quality of life have contributed to the growth during the historic period.

In the coming years, the pruritus therapeutics market size is anticipated to witness solid growth. The market is projected to reach “$15.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is due to a broader understanding of pruritus pathophysiology, advancements in drug formulations and delivery, a focus on tailor-made medicine, growth in dermatological R&D, increasing consciousness and diagnosis rates, and escalating interest in plant-based and herbal remedies. Noteworthy trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, market concentration on individual therapeutic strategies, the amalgamation of technology in itch monitoring and management, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Factors Are Pushing The Pruritus Therapeutics Market Forward?

The pruritus therapeutics market is projected to grow due to an increase in dermatological disorders. These disorders encompass a range of conditions affecting the skin, hair, nail, and mucous membrane, including skin cancer, fungal infections, acne, and eczema. The specific cause of the itch often dictates the type of pruritus treatment used for skin diseases. Treatments may involve topical applications, emollients and moisturizers, medications to suppress the immune system, or drugs to relieve itching. The American Cancer Society, a non-profit organization in the US focused on eradicating cancer, predicted 108,270 cases of skin cancer in January 2024. This marks a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the increasing prevalence of skin disorders is stimulating the growth of the pruritus therapeutics market.

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Redefining The Future Landscape Of The Pruritus Therapeutics Industry?

A key trend in the pruritus therapeutics market is the move by major corporations to develop specifically targeted treatments for unique diseases and specific patient groups. An example of this is the focus on non-systemic ileal bile acid transport inhibitor therapies, which can provide personalized care for previously unaddressed medical needs. This type of medication aims to interfere with bile acid absorption in the gut without significantly impacting the overall circulation of the body, thus reducing potential side effects. In June 2023, a noteworthy example was Ipsen, a pharmaceutical company in France. They obtained approval from the Food and Drug Administration (FDA), a federal agency under the US Department of Health and Human Services, for Bylvay (odevixibat). This drug is used to treat cholestatic pruritus in Alagille syndrome (ALGS) patients ages 12 months and older. Being a non-systemic ileal bile acid transport inhibitor (IBATi) administered once daily, Bylvay only has minor systemic exposure and is currently the first approved therapy for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) within the U.S. Prior to this approval, Bylvay was only authorized for treating PFIC in Europe, but can now be prescribed to eligible ALGS patients.

Which Organizations Are Driving Progress In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Pruritus Therapeutics Industry?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model